Another Study Shows CV Benefits from TRT

[Jinzang]

A ten year study found that hypogonadal men prescribed testosterone undecanoate had fewer major adverse cardiovascular events (MACE) than those who did not receive testosterone. The study also found other cardiovascular markers, such as blood pressure and heart rate imporved on TRT. The results were reported at the annual meating of the American Association of Clinical Endocrinologists. The news report says:

According to the 10-year outcomes of hypogonadal men, fewer men experienced death from a major adverse cardiovascular events (MACE) while on testosterone undecanoate treatment compared with hypogonadal men who weren't on testosterone treatment (4% vs 21.7%). The analysis included a total of 805 men with hypogonadism, defined a a total testosterone of ≤350 ng/dL. Of this group, 676 had clinically defined hypertension or a BP reading of 130/85 mmHg or higher. A total of 376 of these hypogonadal men with hypertension then elected to receive the 3-monthly testosterone undecanoate injections, while 300 men opted against testosterone therapy, and served as the study's controls.